Literature DB >> 18984474

Fibrosis and cirrhosis reversibility - molecular mechanisms.

Roben G Gieling1, Alastair D Burt, Derek A Mann.   

Abstract

The concept that liver fibrosis is a dynamic process with potential for regression as well as progression has emerged in parallel with clinical evidence for remodeling of fibrotic extracellular matrix in patients who can be effectively treated for their underlying cause of liver disease. This article reviews recent discoveries relating to the cellular and molecular mechanisms that regulate fibrosis regression, with emphasis on studies that have used experimental in vivo models of liver disease. Apoptosis of hepatic myofibroblasts is discussed. The functions played by transcription factors, receptor-ligand interactions, and cell-matrix interactions as regulators of the lifespan of hepatic myofibroblasts are considered, as are the therapeutic opportunities for modulating these functions. Growth factors, proteolytic enzymes, and their inhibitors are discussed in detail.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984474     DOI: 10.1016/j.cld.2008.07.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  30 in total

Review 1.  The role of cirrhosis in the etiology of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  J Gastrointest Cancer       Date:  2014-03

2.  Effects of cholestasis on learning and locomotor activity in bile duct ligated rats.

Authors:  Nasrin Hosseini; Hojjatallah Alaei; Mohammad Nasehi; Maryam Radahmadi; Zarrindast Mohammad Reza
Journal:  Malays J Med Sci       Date:  2014-01

Review 3.  Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism.

Authors:  Juliane I Beier; Gavin E Arteel
Journal:  Exp Biol Med (Maywood)       Date:  2012-01

4.  Decreased collagen types I and IV, laminin, CK-19 and α-SMA expression after bone marrow cell transplantation in rats with liver fibrosis.

Authors:  S N Carvalho; D C Lira; G P Oliveira; A A Thole; A C Stumbo; C E Caetano; R G Marques; L Carvalho
Journal:  Histochem Cell Biol       Date:  2010-10-21       Impact factor: 4.304

Review 5.  Advances in alcoholic liver disease.

Authors:  Juliane I Beier; Gavin E Arteel; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2011-02

Review 6.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 7.  Myofibroblast-mediated mechanisms of pathological remodelling of the heart.

Authors:  Karl T Weber; Yao Sun; Syamal K Bhattacharya; Robert A Ahokas; Ivan C Gerling
Journal:  Nat Rev Cardiol       Date:  2012-12-04       Impact factor: 32.419

8.  Relaxin decreases the severity of established hepatic fibrosis in mice.

Authors:  Robert G Bennett; Dean G Heimann; Sudhir Singh; Ronda L Simpson; Dean J Tuma
Journal:  Liver Int       Date:  2013-07-21       Impact factor: 5.828

9.  The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis.

Authors:  Mahmoud Elshal; Nashwa Abu-Elsaad; Amr El-Karef; Tarek Mostafa Ibrahim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-14       Impact factor: 3.000

Review 10.  Myofibroblast secretome and its auto-/paracrine signaling.

Authors:  Ritin Bomb; Mark R Heckle; Yao Sun; Salvatore Mancarella; Ramareddy V Guntaka; Ivan C Gerling; Karl T Weber
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.